Extended Data Fig. 8: Effects of transplanting the immune system from aged uPAR CAR T treated mice.
a–s: 0.5x106 UT or m.uPAR-m.28z cells generated from CD45.1+ mice were infused into 18 months old CD45.2+ mice. 6 weeks later, 0.5x106 CD45.2+CD45.1− were isolated from the bone marrow of these mice and transplanted into aged (18 months old) CD45.1+ mice that had been preconditioned with busulfan (30mg/kg in 3 consecutive days). Transplanted mice, alongside controls young (3 months) and old (18 months old) animals were euthanized 5 weeks later and employed for experiments. a, Percentage of CD45.1 positive cells in the bone marrow (n=3 mice for young, n=4 mice for old, n=4 mice for old mice transplanted with the immune system of aged UT treated mice, n=4 for old mice transplanted with the immune system of aged m.uPAR-m.28z treated mice). b, Percentage of CD3 positive cells from CD45.2 positive cells in the bone marrow (n=4 per group). c, Percentage of CD19 positive cells from CD45.2 positive cells in the bone marrow (n=4 per group). d, Percentage of CD11b positive, CD11c positive or both CD11b and CD11c positive cells from CD45.2 positive cells in the bone marrow (n=4 per group). e, Percentage of double CD11b positive and Ly6G positive cells from CD45.2 positive cells in the bone marrow (n=4 per group). f, Percentage of double CD11b positive and Ly6C positive cells from CD45.2 positive cells in the bone marrow (n=4 per group). g, Percentage of CD45.1 positive cells in the peripheral blood (n=3 mice for young, n=4 mice for old, n=4 mice for old mice transplanted with the immune system of aged UT treated mice, n=4 for old mice transplanted with the immune system of aged m.uPAR-m.28z treated mice). h, Percentage of CD3 positive cells from CD45.2 positive cells in the peripheral blood (n=4 per group). i, Percentage of CD19 positive cells from CD45.2 positive cells in the peripheral blood (n=4 per group). j, Percentage of CD11b positive, CD11c positive or both CD11b and CD11c positive cells from CD45.2 positive cells in the peripheral blood (n=4 per group). k, Percentage of double CD11b positive and Ly6G positive cells from CD45.2 positive cells in the peripheral blood (n=4 per group). l, Percentage of double CD11b positive and Ly6C positive cells from CD45.2 positive cells in the peripheral blood (n=4 per group). m, Percentage of CD45.1 positive cells in the intestinal epithelium (n=3 mice for young, n=4 mice for old, n=4 mice for old mice transplanted with the immune system of aged UT treated mice, n=4 for old mice transplanted with the immune system of aged m.uPAR-m.28z treated mice). n, Percentage of CD3 positive cells from CD45.2 positive cells in the intestinal epithelium (n=4 per group). o, Percentage of CD19 positive cells from CD45.2 positive cells in the intestinal epithelium (n=4 per group). p, Percentage of CD11b positive, CD11c positive or both CD11b and CD11c positive cells from CD45.2 positive cells in the intestinal epithelium (n=4 per group). q, Percentage of double CD11b positive and Ly6G positive cells from CD45.2 positive cells in the intestinal epithelium (n=4 per group). r, Percentage of double CD11b positive and Ly6C positive cells from CD45.2 positive cells in the intestinal epithelium (n=4 per group). s, Relative abundance of microbial genus as determined by metagenomics analysis in each condition (n=5 mice for young, n=5 mice for old, n=4 mice for old mice transplanted with the immune system of aged UT treated mice, n=4 for old mice transplanted with the immune system of aged m.uPAR-m.28z treated mice). Results of 1 independent experiment (a–s). Data are mean ± s.e.m. (a-r). Two-tailed unpaired Student’s t-test (a-r).
